‘We’ve won Gold!’

The OlympiAD trial: who won the gold?

OlympiAD was a phase 3 randomized controlled trial of a PARP inhibitor olaparib for metastatic HER2 negative breast cancer patients harboring a BRCA mutation. Although the OlympiAD trial met its primary endpoint, there are concerns regarding whether olaparib truly improves meaningful outcomes for these patients. In this editorial, I examine these issues in detail. An exploration of these issues...

Won Bae Kim Gold Catalysts Powering Fuel Cells

clicking here. colleagues, clients, or customers by , you can order high-quality copies for your If you wish to distribute this article to others here. following the guidelines can be obtained by Permission to republish or repurpose articles or portions of articles ): January 23, 2013 www.sciencemag.org (this information is current as of The following resources related to this article are ava...

WeVe: When Smart Wearables Meet Intelligent Vehicles

Have we won?

Won - Seob Cho 2005